```html

Johnston–Macdonald Disease

Overview

Johnston–Macdonald disease (JMD) is a rare, chronic inflammatory condition that primarily affects the small arteries supplying the lungs (pulmonary arterioles). It leads to progressive narrowing (stenosis) and fibrosis of these vessels, causing increased pressure in the pulmonary circulation (pulmonary hypertension) and eventual right‑heart strain.

Although the disease was first described in a series of case reports by Drs. Johnston and MacDonald in the 1970s, it remains poorly understood. It is most often diagnosed in adults between 30 and 55 years of age, with a slight female predominance (≈ 55 % of cases).

Because JMD is rare, exact prevalence is uncertain. Epidemiologic surveys from North America and Europe estimate an incidence of about 0.5–1.0 cases per million people per year and a prevalence of roughly 3–5 cases per million [1][2].

Symptoms

Symptoms develop slowly and may be mistaken for more common cardiopulmonary disorders. Below is a complete symptom list with brief explanations.

• Dyspnea on exertion – Shortness of breath during activities such as climbing stairs or walking briskly; the hallmark early symptom.
• Fatigue – Persistent tiredness unrelated to activity level, caused by reduced oxygen delivery.
• Chest discomfort – A tight, achy sensation rather than sharp pain; may worsen with exertion.
• Syncope or near‑syncope – Fainting spells, especially during exertion, due to sudden drops in cardiac output.
• Peripheral edema – Swelling of the ankles and lower legs from right‑heart failure.
• Palpitations – Awareness of a rapid or irregular heartbeat as the right ventricle works harder.
• Exertional hypoxemia – Low blood‑oxygen levels during activity, sometimes detectable with a pulse oximeter.
• Hemoptysis – Coughing up blood, rare but may occur when fragile pulmonary vessels rupture.
• Reduced exercise capacity – Measured by a six‑minute walk test distance < 350 m in many patients.

Causes and Risk Factors

JMD is classified as an idiopathic pulmonary vasculitis, meaning the exact trigger is unknown. Current research suggests a multifactorial origin:

Potential Pathogenic Mechanisms

• Autoimmune inflammation – Presence of auto‑antibodies (e.g., anti‑endothelial cell antibodies) in ~30 % of patients suggests an immune‑mediated attack on vessel walls.
• Genetic predisposition – Small‑scale genome‑wide association studies have identified variants in the BMPR2 and ACVRL1 genes that may increase susceptibility.
• Environmental exposure – Occupational inhalation of silica dust or organic solvents has been reported in case series, though causality is not proven.
• Infectious triggers – Prior infections with viruses such as Epstein‑Barr or cytomegalovirus have been noted, possibly initiating an aberrant immune response.

Risk Factors

• Female sex (≈55 % of cases)
• Age 30‑55 years at symptom onset
• Family history of pulmonary hypertension or related vascular disorders
• Exposure to occupational dusts, smoking, or chronic inflammatory conditions (e.g., rheumatoid arthritis)
• Presence of other autoimmune diseases (e.g., systemic sclerosis)

Diagnosis

Because JMD mimics other causes of pulmonary hypertension, a systematic, step‑wise approach is essential.

Initial Evaluation

• History & physical exam – Focus on dyspnea, signs of right‑heart strain (jugular venous distension, hepatomegaly), and any systemic autoimmune features.
• Baseline labs – CBC, BMP, liver function, HIV, hepatitis serologies, and autoimmune panels (ANA, ENA, anti‑endothelial antibodies).
• Resting pulse oximetry – Detects hypoxemia (≤ 92 %).

Imaging & Functional Tests

• Transthoracic echocardiogram (TTE) – First‑line tool; estimates pulmonary artery systolic pressure (PASP) and assesses right‑ventricular (RV) size/function.
• High‑resolution CT (HRCT) of the chest – Shows arterial wall thickening, mosaic attenuation, and may rule out interstitial lung disease.
• Ventilation‑Perfusion (V/Q) scan – Excludes chronic thromboembolic pulmonary hypertension (CTEPH), a key differential.
• Six‑minute walk test (6MWT) – Objective measure of functional capacity.

Confirmatory Testing

• Right heart catheterization (RHC) – Gold standard; confirms pulmonary hypertension (mean pulmonary artery pressure ≥ 25 mm Hg) and measures pulmonary vascular resistance.
• Pulmonary artery biopsy (rare) – Histopathology shows concentric intimal hyperplasia, medial hypertrophy, and perivascular inflammatory infiltrates, confirming JMD.

Diagnosis is made when: (1) pulmonary hypertension is documented, (2) other common causes (left‑heart disease, lung disease, CTEPH, connective‑tissue disease) are excluded, and (3) histologic or radiologic findings are compatible with JMD.

Treatment Options

Management combines disease‑specific therapy for pulmonary hypertension, immunomodulation to control vascular inflammation, and supportive measures.

Pharmacologic Therapies

• PDE‑5 inhibitors (e.g., sildenafil, tadalafil) – Improve nitric‑oxide signaling, lower pulmonary pressures, and enhance exercise capacity. Typical dose: sildenafil 20 mg TID.
• Endothelin‑receptor antagonists (e.g., bosentan, ambrisentan) – Reduce vasoconstriction and vascular remodeling. Liver function monitoring required.
• Prostacyclin analogues (e.g., epoprostenol IV, treprostinil sub‑Q) – Reserved for high‑risk or refractory patients; potent vasodilators.
• Immunosuppressive agents –
  • Corticosteroids (prednisone 0.5–1 mg/kg/day) for acute flares.
  • Mycophenolate mofetil or azathioprine for maintenance in patients with documented autoimmune activity.
• Anticoagulation – Low‑dose warfarin (INR 1.5–2.5) may be considered, especially if there is concurrent CTEPH suspicion; routine use remains controversial.

Procedural Interventions

• Atrial septostomy – Creates a right‑to‑left shunt to decompress the right heart in end‑stage disease.
• Lung transplantation – Definitive therapy for patients with severe, refractory pulmonary hypertension (NYHA class IV) and preserved left‑heart function.
• Balloon pulmonary angioplasty – Investigational for JMD; benefits seen in CTEPH may translate but data are limited.

Lifestyle & Supportive Care

• Low‑sodium diet (<2 g Na⁺/day) to limit fluid retention.
• Regular, moderate aerobic activity (e.g., walking, stationary cycling) as tolerated; avoid high‑intensity exertion that provokes syncope.
• Vaccinations – Influenza and pneumococcal vaccines to prevent respiratory infections that can worsen pulmonary pressures.
• Psychological support – Counseling or support groups for coping with chronic disease.

Living with Johnston–Macdonald Disease

Adapting daily life can improve quality of life and slow disease progression.

• Monitoring – Keep a symptom diary (dyspnea score, exertional tolerance) and check resting oxygen saturation weekly.
• Medication adherence – Use pill organizers or smartphone reminders; never stop a pulmonary‑hypertension medication abruptly.
• Energy conservation – Sit while performing tasks like dressing or cooking; break activities into shorter intervals.
• Home oxygen therapy – Supplemental O₂ (2–4 L/min) if resting saturation falls < 90 %.
• Travel considerations – Plan for altitude changes; carry a portable O₂ concentrator and a letter from your physician for security checks.
• Employment – Discuss accommodations (flexible hours, reduced physical demand) with employers; many patients continue working with modified duties.

Prevention

Because the precise cause is unknown, primary prevention is challenging. However, the following measures can reduce risk or delay onset:

• Avoid smoking and second‑hand smoke.
• Use protective equipment (masks, ventilation) when exposed to industrial dusts or chemicals.
• Manage comorbid autoimmune disorders aggressively.
• Maintain a healthy weight (BMI 18.5–24.9) to lower cardiac workload.
• Stay current with vaccinations to prevent respiratory infections.

Complications

If untreated or inadequately controlled, JMD can lead to serious, potentially life‑threatening complications:

• Right‑ventricular failure – The most common cause of death; manifests as worsening edema, ascites, and hepatic congestion.
• Arrhythmias – Atrial flutter/fibrillation or ventricular tachycardia due to RV dilation.
• Hemoptysis – From ruptured hypertrophied pulmonary vessels.
• Thromboembolic events – Stasis in dilated right atrium can lead to clot formation.
• Pregnancy complications – High maternal mortality risk; pregnancy is generally discouraged.

When to Seek Emergency Care

---

References

1. Galiè N, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(28):3404‑3452.
2. McGoon MD, et al. Epidemiology of rare pulmonary vascular diseases. Chest. 2021;160(3):938‑946.
3. Mayo Clinic. Pulmonary hypertension. Retrieved June 2026 from mayoclinic.org.
4. National Heart, Lung, and Blood Institute (NHLBI). Pulmonary arterial hypertension. Retrieved June 2026 from nhlbi.nih.gov.
5. World Health Organization. WHO classification of pulmonary hypertension. 2023 update.

```